Bypass  ||| S:0 E:7 ||| NNP
for  ||| S:7 E:11 ||| IN
the  ||| S:11 E:15 ||| DT
prevention  ||| S:15 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
ischemic  ||| S:29 E:38 ||| JJ
stroke  ||| S:38 E:45 ||| NN
Although  ||| S:45 E:54 ||| IN
most  ||| S:54 E:59 ||| RBS
ischemic  ||| S:59 E:68 ||| JJ
strokes  ||| S:68 E:76 ||| NNS
are  ||| S:76 E:80 ||| VBP
thromboembolic  ||| S:80 E:95 ||| VBN
in  ||| S:95 E:98 ||| IN
origin  ||| S:98 E:105 ||| NN
and  ||| S:105 E:109 ||| CC
their  ||| S:109 E:115 ||| PRP$
management  ||| S:115 E:126 ||| NN
is  ||| S:126 E:129 ||| VBZ
endovascular  ||| S:129 E:142 ||| VBN
or  ||| S:142 E:145 ||| CC
medical ||| S:145 E:152 ||| JJ
,  ||| S:152 E:154 ||| ,
some  ||| S:154 E:159 ||| DT
are  ||| S:159 E:163 ||| VBP
hemodynamic  ||| S:163 E:175 ||| VBN
in  ||| S:175 E:178 ||| IN
origin  ||| S:178 E:185 ||| NN
and  ||| S:185 E:189 ||| CC
their  ||| S:189 E:195 ||| PRP$
management  ||| S:195 E:206 ||| NN
may  ||| S:206 E:210 ||| MD
be  ||| S:210 E:213 ||| VB
surgical ||| S:213 E:221 ||| JJ
.  ||| S:221 E:223 ||| .
Extracranial-intracranial  ||| S:223 E:249 ||| JJ
bypass  ||| S:249 E:256 ||| NN
with  ||| S:256 E:261 ||| IN
superficial  ||| S:261 E:273 ||| FW
temporal  ||| S:273 E:282 ||| FW
artery-to-middle  ||| S:282 E:299 ||| FW
cerebral  ||| S:299 E:308 ||| FW
artery  ||| S:308 E:315 ||| FW
( ||| S:315 E:316 ||| -LRB-
MCA ||| S:316 E:319 ||| NNP
)  ||| S:319 E:321 ||| -RRB-
bypass ||| S:321 E:327 ||| NN
,  ||| S:327 E:329 ||| ,
high-flow  ||| S:329 E:339 ||| JJ
interposition  ||| S:339 E:353 ||| JJ
grafts ||| S:353 E:359 ||| NN
,  ||| S:359 E:361 ||| ,
and  ||| S:361 E:365 ||| CC
reconstructive  ||| S:365 E:380 ||| JJ
techniques  ||| S:380 E:391 ||| NNS
have  ||| S:391 E:396 ||| VBP
been  ||| S:396 E:401 ||| VBN
developed ||| S:401 E:410 ||| VBN
.  ||| S:410 E:412 ||| .
Clinical  ||| S:412 E:421 ||| JJ
indications  ||| S:421 E:433 ||| NNS
and  ||| S:433 E:437 ||| CC
efficacy  ||| S:437 E:446 ||| NNS
are  ||| S:446 E:450 ||| VBP
controversial ||| S:450 E:463 ||| JJ
,  ||| S:463 E:465 ||| ,
and  ||| S:465 E:469 ||| CC
this  ||| S:469 E:474 ||| DT
review  ||| S:474 E:481 ||| NN
examines  ||| S:481 E:490 ||| VBZ
current  ||| S:490 E:498 ||| JJ
practices ||| S:498 E:507 ||| NNS
.  ||| S:507 E:509 ||| .
Bypass  ||| S:509 E:516 ||| JJ
surgery  ||| S:516 E:524 ||| NN
is  ||| S:524 E:527 ||| VBZ
indicated  ||| S:527 E:537 ||| VBN
for  ||| S:537 E:541 ||| IN
patients  ||| S:541 E:550 ||| NNS
with  ||| S:550 E:555 ||| IN
athero-occlusive  ||| S:555 E:572 ||| JJ
disease  ||| S:572 E:580 ||| NN
that  ||| S:580 E:585 ||| IN
results  ||| S:585 E:593 ||| NNS
in  ||| S:593 E:596 ||| IN
chronic ||| S:596 E:603 ||| NN
,  ||| S:603 E:605 ||| ,
low  ||| S:605 E:609 ||| JJ
cerebral  ||| S:609 E:618 ||| JJ
blood  ||| S:618 E:624 ||| NN
flow  ||| S:624 E:629 ||| NN
accompanied  ||| S:629 E:641 ||| VBN
by  ||| S:641 E:644 ||| IN
episodes  ||| S:644 E:653 ||| NNS
of  ||| S:653 E:656 ||| IN
ischemic  ||| S:656 E:665 ||| JJ
symptoms ||| S:665 E:673 ||| NNS
.  ||| S:673 E:675 ||| .
Specific  ||| S:675 E:684 ||| JJ
diagnoses  ||| S:684 E:694 ||| NNS
include ||| S:694 E:701 ||| VBP
:  ||| S:701 E:703 ||| :
( ||| S:703 E:704 ||| -LRB-
1 ||| S:704 E:705 ||| LS
)  ||| S:705 E:707 ||| -RRB-
internal  ||| S:707 E:716 ||| JJ
carotid  ||| S:716 E:724 ||| JJ
artery  ||| S:724 E:731 ||| NN
occlusion ||| S:731 E:740 ||| NNS
;  ||| S:740 E:742 ||| :
( ||| S:742 E:743 ||| -LRB-
2 ||| S:743 E:744 ||| LS
)  ||| S:744 E:746 ||| -RRB-
MCA  ||| S:746 E:750 ||| NNP
occlusion  ||| S:750 E:760 ||| NN
and ||| S:760 E:763 ||| CC
,  ||| S:763 E:765 ||| ,
rarely ||| S:765 E:771 ||| RB
,  ||| S:771 E:773 ||| ,
high-grade  ||| S:773 E:784 ||| JJ
MCA  ||| S:784 E:788 ||| NNP
stenosis ||| S:788 E:796 ||| NN
;  ||| S:796 E:798 ||| :
( ||| S:798 E:799 ||| -LRB-
3 ||| S:799 E:800 ||| LS
)  ||| S:800 E:802 ||| -RRB-
vertebrobasilar  ||| S:802 E:818 ||| JJ
atherosclerotic  ||| S:818 E:834 ||| JJ
steno-occlusive  ||| S:834 E:850 ||| JJ
disease ||| S:850 E:857 ||| NN
;  ||| S:857 E:859 ||| :
( ||| S:859 E:860 ||| -LRB-
4 ||| S:860 E:861 ||| LS
)  ||| S:861 E:863 ||| -RRB-
vasculitis  ||| S:863 E:874 ||| VBP
resulting  ||| S:874 E:884 ||| VBG
in  ||| S:884 E:887 ||| IN
severe  ||| S:887 E:894 ||| JJ
occlusive  ||| S:894 E:904 ||| JJ
disease ||| S:904 E:911 ||| NN
;  ||| S:911 E:913 ||| :
and  ||| S:913 E:917 ||| CC
( ||| S:917 E:918 ||| -LRB-
5 ||| S:918 E:919 ||| LS
)  ||| S:919 E:921 ||| -RRB-
moyamoya  ||| S:921 E:930 ||| JJ
disease ||| S:930 E:937 ||| NN
.  ||| S:937 E:939 ||| .
Discouraging  ||| S:939 E:952 ||| VBG
results  ||| S:952 E:960 ||| NNS
from  ||| S:960 E:965 ||| IN
the  ||| S:965 E:969 ||| DT
Extracranial-Intracranial  ||| S:969 E:995 ||| JJ
Bypass  ||| S:995 E:1002 ||| NNP
Trial  ||| S:1002 E:1008 ||| NNP
demonstrated  ||| S:1008 E:1021 ||| VBD
the  ||| S:1021 E:1025 ||| DT
importance  ||| S:1025 E:1036 ||| NN
of  ||| S:1036 E:1039 ||| IN
selecting  ||| S:1039 E:1049 ||| VBG
surgical  ||| S:1049 E:1058 ||| JJ
patients  ||| S:1058 E:1067 ||| NNS
based  ||| S:1067 E:1073 ||| VBN
on  ||| S:1073 E:1076 ||| IN
objective  ||| S:1076 E:1086 ||| JJ
measures  ||| S:1086 E:1095 ||| NNS
of  ||| S:1095 E:1098 ||| IN
hemodynamic  ||| S:1098 E:1110 ||| JJ
insufficiency ||| S:1110 E:1123 ||| NN
.  ||| S:1123 E:1125 ||| .
Two  ||| S:1125 E:1129 ||| CD
such  ||| S:1129 E:1134 ||| JJ
tests  ||| S:1134 E:1140 ||| NNS
are  ||| S:1140 E:1144 ||| VBP
xenon-enhanced  ||| S:1144 E:1159 ||| JJ
computed  ||| S:1159 E:1168 ||| JJ
tomography  ||| S:1168 E:1179 ||| NN
with  ||| S:1179 E:1184 ||| IN
acetazolamide  ||| S:1184 E:1198 ||| JJ
challenge  ||| S:1198 E:1208 ||| NN
and  ||| S:1208 E:1212 ||| CC
positron  ||| S:1212 E:1221 ||| JJ
emission  ||| S:1221 E:1230 ||| NN
tomography  ||| S:1230 E:1241 ||| NN
with  ||| S:1241 E:1246 ||| IN
measurement  ||| S:1246 E:1258 ||| NN
of  ||| S:1258 E:1261 ||| IN
oxygen  ||| S:1261 E:1268 ||| JJ
extraction  ||| S:1268 E:1279 ||| JJ
fraction ||| S:1279 E:1287 ||| NN
.  ||| S:1287 E:1289 ||| .
Perfusion  ||| S:1289 E:1299 ||| JJ
computed  ||| S:1299 E:1308 ||| JJ
tomography  ||| S:1308 E:1319 ||| NN
may  ||| S:1319 E:1323 ||| MD
be  ||| S:1323 E:1326 ||| VB
another ||| S:1326 E:1333 ||| DT
,  ||| S:1333 E:1335 ||| ,
more  ||| S:1335 E:1340 ||| RBR
practical  ||| S:1340 E:1350 ||| JJ
test ||| S:1350 E:1354 ||| NN
.  ||| S:1354 E:1356 ||| .
Surgical  ||| S:1356 E:1365 ||| JJ
series ||| S:1365 E:1371 ||| NN
,  ||| S:1371 E:1373 ||| ,
systematic  ||| S:1373 E:1384 ||| JJ
reviews  ||| S:1384 E:1392 ||| NNS
of  ||| S:1392 E:1395 ||| IN
the  ||| S:1395 E:1399 ||| DT
literature ||| S:1399 E:1409 ||| NN
,  ||| S:1409 E:1411 ||| ,
and  ||| S:1411 E:1415 ||| CC
two  ||| S:1415 E:1419 ||| CD
new  ||| S:1419 E:1423 ||| JJ
randomized  ||| S:1423 E:1434 ||| JJ
clinical  ||| S:1434 E:1443 ||| JJ
trials  ||| S:1443 E:1450 ||| NNS
that  ||| S:1450 E:1455 ||| WDT
use  ||| S:1455 E:1459 ||| VBP
these  ||| S:1459 E:1465 ||| DT
diagnostic  ||| S:1465 E:1476 ||| JJ
techniques  ||| S:1476 E:1487 ||| NNS
reveal  ||| S:1487 E:1494 ||| VBP
contradictory  ||| S:1494 E:1508 ||| JJ
results ||| S:1508 E:1515 ||| NNS
.  ||| S:1515 E:1517 ||| .
Although  ||| S:1517 E:1526 ||| IN
they  ||| S:1526 E:1531 ||| PRP
demonstrate  ||| S:1531 E:1543 ||| VBP
that  ||| S:1543 E:1548 ||| IN
bypass  ||| S:1548 E:1555 ||| JJ
surgery  ||| S:1555 E:1563 ||| NN
has  ||| S:1563 E:1567 ||| VBZ
a  ||| S:1567 E:1569 ||| DT
morbidity  ||| S:1569 E:1579 ||| JJ
rate  ||| S:1579 E:1584 ||| NN
of  ||| S:1584 E:1587 ||| IN
less  ||| S:1587 E:1592 ||| JJR
than  ||| S:1592 E:1597 ||| IN
5 ||| S:1597 E:1598 ||| CD
%  ||| S:1598 E:1600 ||| NN
and  ||| S:1600 E:1604 ||| CC
a  ||| S:1604 E:1606 ||| DT
patency  ||| S:1606 E:1614 ||| JJ
rate  ||| S:1614 E:1619 ||| NN
of  ||| S:1619 E:1622 ||| IN
more  ||| S:1622 E:1627 ||| JJR
than  ||| S:1627 E:1632 ||| IN
95 ||| S:1632 E:1634 ||| CD
% ||| S:1634 E:1635 ||| NN
,  ||| S:1635 E:1637 ||| ,
they  ||| S:1637 E:1642 ||| PRP
have  ||| S:1642 E:1647 ||| VBP
not  ||| S:1647 E:1651 ||| RB
proven  ||| S:1651 E:1658 ||| VBN
a  ||| S:1658 E:1660 ||| DT
clear  ||| S:1660 E:1666 ||| JJ
benefit ||| S:1666 E:1673 ||| NN
.  ||| S:1673 E:1675 ||| .
Patients  ||| S:1675 E:1684 ||| NNS
with  ||| S:1684 E:1689 ||| IN
athero-occlusive  ||| S:1689 E:1706 ||| JJ
disease  ||| S:1706 E:1714 ||| NN
and  ||| S:1714 E:1718 ||| CC
symptoms  ||| S:1718 E:1727 ||| NNS
of  ||| S:1727 E:1730 ||| IN
hemodynamic  ||| S:1730 E:1742 ||| JJ
insufficiency  ||| S:1742 E:1756 ||| NNS
have  ||| S:1756 E:1761 ||| VBP
significant  ||| S:1761 E:1773 ||| JJ
risk  ||| S:1773 E:1778 ||| NN
of  ||| S:1778 E:1781 ||| IN
stroke  ||| S:1781 E:1788 ||| NN
if  ||| S:1788 E:1791 ||| IN
left  ||| S:1791 E:1796 ||| JJ
untreated  ||| S:1796 E:1806 ||| NN
or  ||| S:1806 E:1809 ||| CC
managed  ||| S:1809 E:1817 ||| VBD
medically ||| S:1817 E:1826 ||| RB
.  ||| S:1826 E:1828 ||| .
On  ||| S:1828 E:1831 ||| IN
the  ||| S:1831 E:1835 ||| DT
other  ||| S:1835 E:1841 ||| JJ
hand ||| S:1841 E:1845 ||| NN
,  ||| S:1845 E:1847 ||| ,
surgical  ||| S:1847 E:1856 ||| JJ
intervention  ||| S:1856 E:1869 ||| NN
lacks  ||| S:1869 E:1875 ||| VBZ
supporting  ||| S:1875 E:1886 ||| VBG
evidence ||| S:1886 E:1894 ||| NN
.  ||| S:1894 E:1896 ||| .
Clinicians  ||| S:1896 E:1907 ||| NNP
must  ||| S:1907 E:1912 ||| MD
individualize  ||| S:1912 E:1926 ||| VB
their  ||| S:1926 E:1932 ||| PRP$
management  ||| S:1932 E:1943 ||| NN
recommendations  ||| S:1943 E:1959 ||| NNS
until  ||| S:1959 E:1965 ||| IN
additional  ||| S:1965 E:1976 ||| JJ
data  ||| S:1976 E:1981 ||| NNS
are  ||| S:1981 E:1985 ||| VBP
published  ||| S:1985 E:1995 ||| VBN
or  ||| S:1995 E:1998 ||| CC
further  ||| S:1998 E:2006 ||| JJ
consensus  ||| S:2006 E:2016 ||| NN
develops ||| S:2016 E:2024 ||| VBZ
.  ||| S:2024 E:2026 ||| .
